Naltrexone Treatment for Prolonged Grief Disorder (PGD)
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a study to see how effective oral naltrexone is as treatment for prolonged grief
disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly
visits to assess symptom severity, social connectedness, and adverse reactions.
Phase:
Phase 4
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)